Learning outcomes
By the end of this lesson you should be able to: describe the four classical vaccine types and give a named example of each; explain why live and killed vaccines differ in immune response, contraindication and dosage; state what an adjuvant does and why aluminium salts and oil emulsions are used; calculate and interpret a herd immunity threshold for a given basic reproduction number; list the vaccines of the national immunisation schedule with their ages; enumerate the contraindications to vaccination; and explain cold-chain maintenance and vaccine-associated adverse events.
Prerequisites
Lessons 6, 7 and 8. A vaccine works by generating the humoral and cell-mediated responses you have studied, and its assay is a labelled immunoassay read of the antibody produced.
The big idea
Everything you learned about primary and secondary responses is the design specification for a vaccine. The primary response is slow and makes IgM; the secondary is fast, makes IgG and is high-affinity. A vaccine is therefore an attempt to buy the first encounter early, deliberately and without the risk of disease, so that the real encounter is a secondary response. Since Edward Jenner's 1796 experiment with cowpox, everything else has been engineering: how to present antigen safely, how to make it elicit both arms, and how to deliver it to enough of a population.
There are two parameters a vaccine must satisfy. Efficacy is the reduction in disease in a vaccinated person under ideal conditions; effectiveness is what happens in the real world, where cold chains break and doses are missed. Neither matters if population coverage fails: herd immunity is what protects the vaccinated and unvaccinated alike, and its threshold is set by how transmissible the organism is.
Vaccine types
| Type | Composition | Immune response | Named examples | Advantages and drawbacks |
|---|---|---|---|---|
| Live attenuated | A weakened organism that still replicates but does not cause disease in the immunocompetent host | Both humoral and cell-mediated; long-lasting, often lifelong immunity | BCG, measles–mumps–rubella, varicella, yellow fever, oral typhoid Ty21a, rotavirus | Strong response with usually one or two doses; contraindicated in pregnancy and immunodeficiency; needs a cold chain; can rarely revert (vaccine-associated paralytic poliomyelitis) |
| Killed or inactivated | Whole organism rendered non-replicating | Mainly humoral; boosting required | Inactivated poliovirus (Salk), Japanese encephalitis, inactivated influenza, inactivated hepatitis A, whole-cell pertussis | Safe in immunocompromised hosts; needs several doses and boosters |
| Subunit, toxoid and polysaccharide | A purified component rather than the whole organism | Humoral only | Acellular pertussis, tetanus and diphtheria toxoids, pneumococcal polysaccharide, meningococcal polysaccharide | Very safe and well tolerated; weaker immunogenicity, so polysaccharides need conjugation |
| Conjugate | A polysaccharide chemically bonded to a carrier protein | T-dependent humoral response with memory | Hib (Haemophilus influenzae type b), pneumococcal conjugate, meningococcal C and ACWY conjugates | Works in infants, memory, and herd protection; expensive |
| Recombinant protein / virus-like particle | Antigen produced in yeast or another cell; empty shells of capsid protein | Strong humoral response | Hepatitis B (HBsAg from yeast), human papillomavirus L1 virus-like particles | No risk of infection, cannot replicate; needs adjuvant and multiple doses |
| Viral vector | A harmless virus engineered to carry the gene for the antigen | Strong humoral and cellular response | Ebola vaccine (VSV Ebola Zaire), the Oxford–AstraZeneca and Janssen COVID-19 vaccines | Efficient gene delivery; pre-existing immunity to the vector can blunt the response |
| Messenger RNA | Nucleic acid encoding the antigen, in a lipid nanoparticle | Humoral and cellular, with a strong interferon response | The Pfizer–BioNTech and Moderna COVID-19 vaccines | Fast design and manufacture; requires very cold storage and multiple doses |
NoteBCG is the exception to everything and is worth understanding on its own terms. It is live attenuated Mycobacterium bovis, obtained by 230 serial passages on glycerinated potato bile medium over 13 years — attenuation by culture, not by engineering. It protects infants against disseminated and meningeal tuberculosis, gives little protection against adult pulmonary disease, leaves a small scarred tuberculin response that complicates later interpretation, and is the standard example of a live bacterial vaccine.
Adjuvants and delivery
| Adjuvant | Mechanism | Used in |
|---|---|---|
| Aluminium salts (alum) | Depot formation and NLRP3 inflammasome activation, favouring a Th2 antibody response | Diphtheria, tetanus, pertussis and hepatitis B vaccines |
| MF59 (oil-in-water emulsion) | Recruits myeloid cells and enhances antigen uptake | Seasonal influenza vaccine for the elderly |
| AS01 (liposome with a TLR4 and TLR7 agonist) | Strong innate activation producing both humoral and cellular response | Shingles (Zoster) and malaria RTS,S vaccines |
| CpG oligonucleotides (TLR9 agonists) | Direct innate stimulation favouring a Th1 response | Hepatitis B recombinant vaccine |
A purified recombinant antigen with no PAMP is, to the innate system, indistinguishable from any harmless protein. An adjuvant supplies the missing danger signal, so the dendritic cell matures and the T-cell help that drives class switching and memory becomes available. This is also why subunit and mRNA vaccines, which are otherwise beautifully safe, could not have worked without adjuvants.
Herd immunity
| Disease | Basic reproduction number R0 | Herd immunity threshold | Practical implication |
|---|---|---|---|
| Measles | About 12–18, the highest known for a vaccine-preventable human disease | 92–95 per cent | Coverage below 95 per cent produces outbreaks — the reason for the second MMR dose and for the summer campaigns |
| Polio | About 5–7 | 80–86 per cent | Eradication is feasible but requires near-complete coverage in the last reservoirs |
| Diphtheria | About 6–7 | 85 per cent | The historical benefit of routine infant immunisation |
| Pertussis | About 12–17 | 92–94 per cent | A high threshold and waning immunity explain the resurgence where coverage drops |
| COVID-19 | Estimated around 2–3 in early variants | 50–67 per cent | A moving target, raised by variants and waning immunity |
Watch outHerd immunity is a population property, not an individual one, and it is destroyed by clusters of unvaccinated people. A coverage rate of 97 per cent nationally can still permit a measles outbreak in a community with 70 per cent coverage, because transmission needs contacts rather than a national average. Outbreak control therefore means finding the under-immunised, not counting the national tally.
The national immunisation schedule
In India the Universal Immunisation Programme delivers a defined schedule to every child, with the timing set by the epidemiology of each organism: BCG at birth because tuberculosis is endemic and the benefit is greatest against disseminated infant disease; oral polio at birth to interrupt faecal-oral transmission early; and hepatitis B at birth because there is currently a window of time before any other protection. The diphtheria, pertussis, tetanus, Haemophilus influenzae type b and hepatitis B pentavalent vaccine is given at 6, 10 and 14 weeks, matching the infant's ability to make a T-dependent response while the window of pertussis lethality is open.
| Age | Vaccine | Notes |
|---|---|---|
| Birth | BCG, oral polio vaccine, hepatitis B birth dose | BCG given intradermally in the left upper arm; hepatitis B within 24 hours where possible |
| 6 weeks | Pentavalent 1, inactivated polio 1, rotavirus 1, pneumococcal conjugate 1, influenza in some states | Pentavalent covers diphtheria, pertussis, tetanus, Hib and hepatitis B |
| 10 weeks | Pentavalent 2, polio 2, rotavirus 2, pneumococcal 2 | Complete the primary series in the first three months |
| 14 weeks | Pentavalent 3, polio 3, rotavirus 3, pneumococcal 3 | The last primary dose — continuing past 14 weeks does not eliminate the need to complete |
| 9 months | Measles-containing vaccine 1, Japanese encephalitis in endemic districts, vitamin A | Measles at 9 months balances maternal antibody decay against the lethality of infant measles |
| 16–24 months | DPT booster 1, polio booster, measles-containing vaccine 2 | The second MR restores primary vaccine failures |
| 5 years | DPT booster 2 | Maintains diphtheria and pertussis protection |
| 10 years | Tetanus and adult diphtheria (Td) | A toxoid booster, thereafter every 10 years |
| 16 years | Td booster | Protects through the child-bearing years |
| Pregnant women | Tetanus and diphtheria (Td), and rubella where included | Protects the neonate through transplacental antibody and prevents neonatal tetanus |
NoteThe cold chain runs at 2–8°C from manufacture to point of use, with temperature monitoring every step and control of freezing for the freeze-sensitive vaccines. A vaccine vial monitor on a messenger RNA vaccine, and the visible loss of potency in one that has frozen, are the practical answer to the observation that the last kilometre of the supply chain is where vaccines most often die.
Contraindications and precautions
| Situation | Which vaccine is implicated | Action |
|---|---|---|
| Anaphylaxis to a previous dose or a component | Any vaccine | Do not give that vaccine again; assessment by an allergist before further doses |
| Severe combined immunodeficiency | All live vaccines (BCG, MMR, oral polio, varicella) | Withhold; risk of disseminated infection from the vaccine strain |
| Pregnancy | All live vaccines | Withhold routine live vaccines; give inactivated vaccines such as Td and inactivated influenza where indicated |
| HIV with advanced immunosuppression | Live vaccines, particularly BCG and varicella | BCG is contraindicated in symptomatic HIV; MMR is given if CD4 is adequate |
| Egg allergy | Influenza vaccine grown in eggs (and yellow fever) | Modern guidance permits vaccination under supervision; true anaphylaxis to egg requires a specialist setting |
| Acute febrile illness | Any vaccine temporarily | Delay until recovery; a mild illness with low-grade fever is not a contraindication |
| Antibiotics and low-dose steroids | Live vaccines | Not a contraindication; only immunosuppressive doses of steroids are |
Watch outThe most common real-world error is postponing vaccination for a trivial reason — a runny nose, a mild cough, the child teething, a previously decided 'rest day'. Each deferral is a further window of susceptibility, and the lost dose disproportionately affects the children who need it most. Vaccinate a child who is well, and only a moderate or severe acute illness genuinely warrants delay.
Adverse events and surveillance
Most vaccine reactions are local and self-limiting: pain, swelling at the injection site, low-grade fever, and irritability. Serious adverse events are rare but must be recognised, and they are classified as an adverse event following immunisation, which is a temporal association requiring investigation rather than a proven causal relationship.
| Event | Vaccine and mechanism | Frequency and management |
|---|---|---|
| Febrile seizure | MMR, by the febrile response | About 1 in 3,000 doses; children recover without sequelae, and antipyretic management is available |
| Anaphylaxis | Any vaccine, rare | About 1 in a million doses; treated immediately with adrenaline, and the reason for a 15-minute observation period |
| Vaccine-associated paralytic poliomyelitis | Oral live polio vaccine, from reversion of the vaccine strain | About 1 case per 2.4 million doses; the reason inactivated polio vaccine replaced oral vaccine in most schedules |
| Intussusception | Rotavirus vaccine, historically rhesus-human reassortant strains | Low absolute excess risk; the current vaccines carry a much smaller attributable risk |
| Syncope | Any vaccine in adolescents | Preventable by vaccination in a seated position; managed by observation |
Surveillance systems monitor these signals continuously and can act on them — withdrawal of a rotavirus product in 1999, the switch of oral to inactivated polio, and monitoring of rare thrombotic events after adenoviral-vector COVID-19 vaccines are all examples of the system working. The regulatory answer to the question 'is the vaccine safe?' is: safety is a continuous, monitored property, not a single pre-licence result.
Common mistakes
Watch outBelieving a live vaccine can be given to an immunocompromised patient. BCG given to a symptomatic HIV-positive infant can disseminate and kill, and varicella vaccine in a T-cell-deficient child can cause progressive disease. Live vaccines are withheld in significant immunodeficiency and in pregnancy, and inactivated vaccines are used instead.
Watch outThinking adults are finished with immunisation. Tetanus needs a booster every ten years, and the acellular pertussis-containing booster exists because pertussis protection wanes. Adult schedules offer influenza annually, pneumococcal vaccination above 65, hepatitis B, and the shingles vaccine — each of which answers a waning immune response in an ageing population.
Watch outConfusing herd immunity with individual immunity and treating a vaccination rate as evidence that a particular patient is protected. An unvaccinated child in an outbreak is exposed whenever a case walks into the classroom, and the protection given by herd immunity lasts exactly as long as nobody's coverage slips.
Check your understanding
Calculate the herd immunity threshold for measles, given a basic reproduction number of 15, and explain what coverage rate that implies.
Why can a live attenuated vaccine usually give strong immunity with one dose while a killed vaccine requires several?
A 6-week-old infant has a mild runny nose and a temperature of 37.6°C, and is due for the second pentavalent dose. What should be done and why?
Multiple choice
Which is a defining property of a live attenuated vaccine?
A basic reproduction number of 12 for pertussis gives a herd immunity threshold closest to which figure?
Which statement about BCG is correct?
Summary and next
Vaccines apply the primary and secondary antibody and T-cell responses you have studied, and are classified as live attenuated, killed inactivated, subunit or toxoid, conjugate, recombinant, viral-vector and messenger RNA. Adjuvants supply the danger signal that a purified antigen lacks; coverage above the herd immunity threshold of 1 − 1/R0 protects even the unvaccinated; and the national schedule delivers a defined set of vaccines at ages matched to each organism's epidemiology and the infant's ability to respond. Live vaccines are withheld in immunodeficiency and in pregnancy, and safety is a continuously monitored property rather than a single pre-licence result.
Module 2 ends here. Module 3 opens with general virology: virion structure and replication, the cultivation of viruses in cells and eggs, and laboratory diagnosis of an obligate intracellular parasite that cannot be grown on agar.